In the news: only 1 of 25 cancer drug developers fairly included minority patients 🗞 Despite policy efforts to improve patient diversity in clinical research, under-representation of women, older adults, and racial & ethnical minorities remains a persistent problem. A recent study published in the BMJ, developed baseline quality measures for fair inclusion in clinical research, capturing transparency of patient demographics & inclusion of under-represented groups. After applying these quality measures on 59 cancer drugs approved by the FDA, the study concluded only 1/25 sponsor companies scored well on both transparency & representation scores, signalling a significant need for improvement. At Triall, we support sponsors with accessing a more diverse patient pool through tools such as eConsent & ePRO, and through patient recruitment services offered by our partner network. 👉 More info: twitter.com/triallofficial/status/1616061853020426243?s=20&t=3PN-H9JAOE1MbSVCP7GUWg #blockchainforhealth #TRL

In the news: only 1 of 25 cancer drug developers fairly included minority patients 🗞 Despite policy efforts to improve patient diversity in clinical research, under-representation of women, older adults, and racial & ethnical minorities remains a persistent problem. A recent study published in the BMJ, developed baseline quality measures for fair inclusion in clinical research, capturing transparency of patient demographics & inclusion of under-represented groups. After applying these quality measures on 59 cancer drugs approved by the FDA, the study concluded only 1/25 sponsor companies scored well on both transparency & representation scores, signalling a significant need for improvement. At Triall, we support sponsors with accessing a more diverse patient pool through tools such as eConsent & ePRO, and through patient recruitment services offered by our partner network. 👉 More info: twitter.com/triallofficial/status/1616061853020426243?s=20&t=3PN-H9JAOE1MbSVCP7GUWg #blockchainforhealth #TRL